Status:
COMPLETED
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Lead Sponsor:
Stanford University
Conditions:
Non-small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individua...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Limited primary non-small cell lung cancers (NSCLC) (ie, graded as T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0), or metastatic lung tumors with no evidence of uncontrolled extrathoracic metastases.
- Up to 4 lesions may be considered.
- For a single lesion, the sum of three orthogonal diameters can be no more than 20 cm.
- For multiple lesions, no lesion can have a sum of orthogonal diameters greater than 15 cm.
- Both peripheral and central tumors are accepted for this trial.
- Age ≥ 18 years old
- Patients may be enrolled more than once (eg, for a new tumor lesion)
- EXCLUSION CRITERIA
- Contraindication for radiotherapy
- Pregnant and breastfeeding women are excluded
- If prior radiation therapy, there is no overlap with the prior high dose regions (EXCEPTION: by approval of the investigators).
Exclusion
Key Trial Info
Start Date :
October 21 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 7 2022
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT01463423
Start Date
October 21 2011
End Date
February 7 2022
Last Update
December 19 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Cancer Institute
Stanford, California, United States, 94305
2
Swedish Cancer Institute
Seattle, Washington, United States, 98104
3
Princess Margaret Cancer Center
Toronto, Ontario, Canada, ON M5G 2M9
4
Hokkaido University Hospital
Sapporo, Hokkaido, Japan